Home›Trial›NCT06360289
NCT06360289RECRUITING

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

Study Summary

This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR variants and symptomatic hATTR amyloidosis patients with polyneuropathy.

Conditions
Hereditary Amyloidosis, Transthyretin-RelatedAsymptomatic Carrier State
Interventions / Drugs
Standard of Care
View on ClinicalTrials.gov ↗
Sponsor
ALNY
Alnylam Pharmaceuticals
RNAi Therapeutics
F27/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219234+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 500 participants
Sponsor Catalyst Profile

Alnylam Pharmaceuticals (ALNY) is the sponsoring company for this trial. BiotechSign currently grades this company F (27/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ALNY Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.